Wells Fargo
INMB icon

Wells Fargo’s INmune Bio INMB Stock Holding History

Wells Fargo’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12K Sell
10,642
-14,215
-57% -$20.3K ﹤0.01% 5928
2025
Q4 		$38.8K Buy
24,857
+10,970
+79% +$19.6K ﹤0.01% 5632
2025
Q3 		$28.7K Buy
13,887
+4,204
+43% +$9.62K ﹤0.01% 5704
2025
Q2 		$22.4K Buy
9,683
+3,165
+49% +$23.2K ﹤0.01% 5766
2025
Q1 		$50.9K Buy
6,518
+141
+2% +$1.12K ﹤0.01% 5393
2024
Q4 		$29.8K Buy
6,377
+2,155
+51% +$11.2K ﹤0.01% 5648
2024
Q3 		$22.8K Buy
4,222
+259
+7% +$1.84K ﹤0.01% 5610
2024
Q2 		$35K Buy
3,963
+3,816
+2,596% +$37.6K ﹤0.01% 5420
2024
Q1 		$1.73K Buy
147
+2
+1% +$24 ﹤0.01% 6058
2023
Q4 		$1.63K Sell
145
-2,219
-94% -$18.6K ﹤0.01% 6134
2023
Q3 		$16K Sell
2,364
-865
-27% -$7.17K ﹤0.01% 5677
2023
Q2 		$29.3K Sell
3,229
-152
-4% -$1.22K ﹤0.01% 5622
2023
Q1 		$21.8K Sell
3,381
-4,222
-56% -$34K ﹤0.01% 5600
2022
Q4 		$48.2K Sell
7,603
-5,075
-40% -$36K ﹤0.01% 4877
2022
Q3 		$78K Sell
12,678
-949
-7% -$8.33K ﹤0.01% 4741
2022
Q2 		$121K Sell
13,627
-589
-4% -$4.38K ﹤0.01% 4537
2022
Q1 		$120K Buy
14,216
+2,707
+24% +$24.3K ﹤0.01% 5228
2021
Q4 		$118K Buy
11,509
+8,882
+338% +$131K ﹤0.01% 5544
2021
Q3 		$51K Buy
2,627
+2,575
+4,952% +$49.7K ﹤0.01% 5616
2021
Q2 		$1K Hold
52
– – ﹤0.01% 6674
2021
Q1 		$1K Buy
52
+12
+30% +$216 ﹤0.01% 6726
2020
Q4 		$1K Hold
40
– – ﹤0.01% 6351
2020
Q3 		$0 Buy
40
+17
+74% +$173 ﹤0.01% 6583
2020
Q2 		$0 Buy
23
+1
+5% +$5 ﹤0.01% 6530
2020
Q1 		$0 Buy
+22
New +$99 ﹤0.01% 6473

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo's INMB Position: Q1 2026 in Review

Wells Fargo reduced its INmune Bio (INMB) stake by 57% in Q1 2026, selling an estimated $20.3K and leaving 10,642 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #5928.

Wells Fargo first reported a position in INMB in Q1 2020 and has held it in 25 quarters since. The position peaked at $121K in Q2 2022. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Wells Fargo held 10,642 shares of INmune Bio worth $12K as of Q1 2026.
  • Wells Fargo sold 14,215 INmune Bio shares in Q1 2026, an estimated $20.3K.
  • INmune Bio made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5928 holding.
  • Wells Fargo first reported a position in INmune Bio in Q1 2020 and has held it in 25 quarters since.
  • Wells Fargo's INmune Bio position peaked at $121K in Q2 2022.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.